Integrated Research Platforms (IRPs) and platform trials are relatively new and consequently the vocabulary is work in progress. The EU-PEARL project wrote and published the document for a common understanding and usage of terminology.
This new resource intends and to promote the use of a standard terminology across the sphere of platform trials research. The document includes key terms that range from to break down any potential barriers to communicate with the wider world comprehensive definitions of master protocol elements and its different types, to statistical terminology or biomarkers terms.
EU-PEARL is a strategic partnership between the public and private sectors to shape the future of clinical trials. This innovative and challenging enterprise aims to create a tested and trusted framework for patient-centric integrated research platform (IRP) trials, through which novel techniques and treatments developed by multiple companies and organizations are tested in a platform trial.
To achieve this objective, EU-PEARL promotes cooperation amongst pharmaceutical companies, clinicians, patients and researchers and encourages knowledge sharing and open discussion amongst all stakeholders, including regulators.
EU-PEARL is funded by Horizon 2020 and the Innovative Medicines Initiative (IMI) under grant agreement number 853966-2.
for articles/videos/studies
Healthcare professionals who wish to be part of a unique network, providing access to up-to-date, accurate and validated information about clinical research.
Investigators and study staff who wish to be part of a unique network, in order to stay abreast of clinical trials taking place in Luxembourg and who are willing to further develop their competencies.
